BCR-ABL inhibitors in chronic myeloid leukemia: Process chemistry and biochemical profile

Current Medicinal Chemistry

Volumn 18, Issue 19, 2011, Pages 2943-2959

  Leonetti, F ^a   Stefanachi, A ^a   Nicolotti, O ^a   Catto, M ^a   Pisani, L ^a   Cellamare, S ^a   Carotti, A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

BCR ABL; Chronic myeloid leukemia; Process chemistry; T315I mutation; Tyrosine kinase inhibitors

Indexed keywords

BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

CHEMICAL REACTION; CHRONIC MYELOID LEUKEMIA; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS;

EID: 79960023243     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796150414     Document Type: Review

References (111)

1. Geary, C. G. The story of chronic myeloid leukaemia. Br. J. Haematol., 2000, 110, 2-11. (Pubitemid 30625590)
2. Goldman, J. M. Chronic myeloid leukemia: a historical perspective. Semin. Hematol., 2010, 47, 302-311.
3. Bartram, C. R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M.; and coll. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 1983, 306, 277-280. (Pubitemid 14232360)
4. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer., 2005, 5, 172-183. (Pubitemid 40314949)
5. Hazlehurst, L. A.; Bewry, N. N.; Nair, R. R.; Pinilla-Ibarz, J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control., 2009, 16, 100-107.
6. Wetzler, M.; Talpaz, M.; Estrov, Z.; Kurzrock, R. CML: mechanisms of disease initiation and progression. Leuk. Lymphoma, 1993, 11, 47-50. (Pubitemid 23274136)
7. Chen, Y.; Peng, C.; Li, D.; Li, S. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell., 2010, 1, 124-132.
8. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344, 1031-1037. (Pubitemid 32267972)
9. Capdeville, R.; Buchdunger, E.; Zimmermann, J., Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 2002, 1, 493-502.
10. Agrawal, M.; Garg, R. J.; Cortes, J.; Quintás-Cardama, A. Tyrosine kinase inhibitors: the first decade. Curr. Hematol. Malig. Rep., 2010, 5, 70-80.
11. Kantarjian, H. M.; Talpaz, M.; Giles, F.; O'Brien, S.; Cortes, J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med., 2006, 145, 913-923. (Pubitemid 351639967)
12. Walz, C.; Sattler, M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit. Rev. Oncol. Hematol., 2006, 57, 145-164. (Pubitemid 43140744)
13. Kujawski, L.; Talpaz, M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk. Lymphoma, 2007, 48, 2310-2322. (Pubitemid 350253462)
14. Mahon, F. X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res., 2008, 68, 9809-9816.
15. Matthews, D. J.; Gerritsen, M. E. Targeting Protein Kinases for Cancer Therapy; Wiley & Sons: Hoboken, New Jersey, 2010.
16. Li, R.; Stafford, J. A. Kinase Inhibitors Drugs; Wiley & Sons: Hoboken, New Jersey, 2009.
17. Fabbro, D.; McCormick, F. Protein Tyrosine Kinases: from Inhibitors to Useful Drugs; Humana Press: Totowa, New Jersey, 2010.
18. Bumbea, H.; Vladareanu, A. M.; Voican, I.; Cisleanu, D.; Barsan, L.; Onisai, M. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors, the first molecular targeted treatment. J. Med. Life, 2010, 3, 162-166.
19. Jabbour, E.; Kantarjian, H.; Cortes, J.; Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin. Hematol., 2010, 47, 344-353.
20. An, X.; Tiwari, A. K.; Sun, Y.; Ding, P. R.; Ashby, C. R. Jr; Chen, Z. S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res., 2010, 34, 1255-1268.
21. Quintás-Cardama, A.; Kantarjian, H.; Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin. Hematol., 2010, 47, 371-380.
22. http://journals.lww.com/oncologytimes/Fulltext/2010/02101/Third-Generati on-Tyrosine-Kinase-Inhibitors-Show.3.aspx
23. Cilloni, D.; Messa, E.; Rotolo, A.; Saglio, G. Emerging drugs for chronic myeloid leukemia. Expert Opin. Emerg. Drugs, 2010, 15, 175-184.
24. Schenone, S.; Brullo, C.; Botta, M. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr. Med. Chem., 2010, 17, 1220-1245.
25. Anastas, P. T.; Williamson, T. C. "Green Chemistry"; Oxford University Press, 2000.
26. Gadamasetti, K. G. Process Chemistry in the Pharmaceutical Industry; CRC Press, 1999.
27. Gadamasetti, K. G.; Braish, T. Process Chemistry in the Pharmaceutical Industry - Challenges in an Ever Changing Climate; CRC Press, 2007.
28. Anderson, N. G. Practical process research & development; Academic Press, 2000.
29. Levin, M. Pharmaceutical Process Scale-Up; Marcel Dekker, Inc., 2001.
30. Li, J.; Gong, J. F.; Wu, A. W.; Shen, L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur. J. Surg. Oncol., 2011, doi:10.1016/j.ejso.2011.01.005
31. Melnikova, I.; Golden, J. Targeting protein kinases. Nat. Rev. Drug Discov., 2004, 3, 993-994. (Pubitemid 39642356)
32. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S. Effects of a selective inhibitor of the Abl tyrosine kinase in chronic myeloid leukemia. Nat. Med., 1996, 9, 561-566.
33. Mauro, M. J.; Druker, B. J. STI571: Targeting BCR-ABL as therapy for CML. Oncologist, 2001, 6, 233-238. (Pubitemid 32592214)
34. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathman, I.; Kantarjian, H.; Gatterman, N. Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 2006, 355, 2408-2417. (Pubitemid 44903745)
35. Nagar, B.; Bormann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 2002, 62, 4236-4243. (Pubitemid 34827278)
36. Schindler, T.; Bornmann, W. G.; Pellicena, P.; Miller, W. T.; Clarckson, B.; Kuriyan, J.; Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science, 2000, 289, 1938-1942.
37. Le Coutre, P.; Tassi, E.; Varella-Garcia, M. Induction of resistance to the abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 2000, 95, 1758-1766. (Pubitemid 30120840)
38. (a) White, D. L.; Saunders, V. A.; Dang, P. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 2007, 110, 4064-4072. (Pubitemid 350248463)
39. (b) Gambacorti-Passerini, C.; Zucchetti, M.; Russo, D.; Frapolli, R.; Verga, M.; Bungaro, S.; Tornaghi, L.; Rossi, F.; Pioltelli, P.; Pogliani, E.; Alberti, D.; Corneo, G.; D'Incalci, M. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin. Cancer. Res., 2003, 9, 625-632. (Pubitemid 36182594)
40. Apperley, J. F. Part I: Mechanism of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol., 2007, 8, 1018-1029. (Pubitemid 47629897)
41. (b) Apperley, J. F. Part II: management of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol., 2007, 12, 1116-1128. (Pubitemid 350182968)
42. Press, R. D. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy. The Oncologist, 2010, 15, 744-749.
43. (a) Zimmermann, J. Pyrimidinderivative und verfahren zu ihrer herstellung. EP Patent 564, 409, March 23, 1993.
44. (b) Zimmermann, J. Pyrimidine derivatives and processes for the preparation thereof. U. S. Patent 5, 521, 184, May 28, 1996.
45. (c) Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett., 1996, 9, 1221-1226;
46. (d) Zimmermann, J.; Sutter, B.; Burger, H. M. Crystal modification of a N-phenyl-2-pyrimidine amine derivative, processes for its manufacture and its use. Republic of South Africa Patent 986362, January 22, 1999.
47. Loiseleur, O.; Kaufmann, D.; Abel, S.; Buerger, H. M.; Meisenbach, M.; Schmitz, B.; Sedelmeier, G. N-phenyl-2-pyrimidine-amine derivatives. W. O. Patent 03/066613, August 14, 2003.
48. Kompella, A.; Bhujanga Rao, A. K. S.; Venkaiah Chowdary, N. Process for the preparation of the anti-cancer drug imatinib and its analogues. W. O. Patent 2004/108699, December 16, 2004.
49. Szakacs, Z.; Beni, S.; Varga, Z.; Orfi, L.; Keri, G.; Noszal, B. J. Med. Chem., 2005, 48, 249-255.
50. Leonetti, F.; Capaldi, C.; Carotti, A. Microwave-assisted solid phase synthesis of imatinib, a blockbuster anticancer drug. Tetrahedron Lett., 2007, 48, 3455-3458. (Pubitemid 46574778)
51. Hopkin, M. D.; Baxendale, I. R.; Ley, S. V. An Automated Flow-Based Synthesis of Imatinib: the API of Gleevec. Chem. Commun., 2010, 46, 2450-2452.
52. Liu, Y.-F.; Wang, C.-L; Bai, Y.-J.; Han, N.; Jiao, J.-P; Qi, X.-L. A facile total synthesis of imatinib base and its analogues. Org. Process Res. Dev., 2008, 12, 490-495.
53. Martinelli, G.; Soverini, S.; Rosti, G.; Baccarani, M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 2005, 1-8.
54. Gora-Tybor, J.; Robak, T. Targeted drugs in chronic myeloid leukemia. Curr. Med. Chem., 2008, 15, 3036-3051.
55. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res., 2006, 66, 5790-5797. (Pubitemid 43927133)
56. "Dasatinib versus Imatinib Study in treatment wild-type CML Patients" DASISION study. http://clinicaltrials.gov/ct2/results?term= DASISION
57. Kantarjian, H.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 2010, 362, 2260-2270.
58. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2- methyl-4-pyrimidinyl]amino)]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem., 2006, 49, 6819-6832. (Pubitemid 44749749)
59. Chen, B.-C.; Zhao, R.; Wang, B.; Droghini, R.; Lajeunesse, J.; Sirard, P.; Endo, M; Balasubramanian, B.; Barrish J. C. A new and efficient preparation of 2-aminothiazole-5-carbamides: applications to the synthesis of the anticancer drug dasatinib. Arkivoc, 2010, VI, 32-38.
60. Deininger, M. W. Nilotinib. Clin. Cancer Res., 2008, 14, 4027-4031.
61. Redaelli, S.; Piazza, R.; Rostagno, R.; Magistroni, V.; Perini, P.; Marega, M.; Gambacorti-Passerini, C.; Boschelli, F. Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR-ABL mutants. J. Clin. Oncol., 2009, 27, 469-471.
62. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brueggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141. (Pubitemid 40248339)
63. Manley, P. W.; Stiefl, N.; Cowan-Jacob, S. W.; Kaufman, S.; Mestan, J.; Wartmann, M.; Wiesmann, M.; Woodman, R.; Gallagher, N. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem., 2010, 18, 6977-6986.
64. Jabbour, E.; Branford, S.; Saglio, G.; Jones, D.; Cortes, J. E.; Kantarjian, H. M. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer, 2011, 117, 1800-1811.
65. Agrawal, M; Garg, R. J.; Kantarjian, H.; Cortes, J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr. Oncol. Rep., 2010, 12, 302-313.
66. Jabbour, E.; Hochhaus, A.; Cortes, J.; La Rosée, P.; Kantarjian, H. M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia, 2010, 24, 6-12.
67. Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients Study, ENESTnd Study. http://clinicaltrials.gov/ct2/results? term=ENESTnd
68. Saglio, G.; Kim, D. W.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C. Nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 2010, 362, 2251-2259.
69. Sawyers, C. L. Even better kinase inhibitors for chronic myeloid leukemia. N. Engl. J. Med., 2010, 362, 2314-2315.
70. Breitenstein, W.; Furet, P.; Jacob, S.; Manley, P. W. Inhibitors of tyrosine kinases. W. O. Patent 2004005281, January 15, 2004.
71. Huang, W. S.; Shakespeare, W. C. An efficient synthesis of Nilotinib (AMN107). Synthesis, 2007, 14, 2121-2124. (Pubitemid 47122970)
72. O'Hare, T.; Shakespeare, W. C.; Zhu, X.; Eide, C. A.; Rivera, V. M.; Wang, F. AP24534, a pan BCR-ABL inhibitor for chronic myeloid leukemia potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16, 401-412.
73. Huang, W. S.; Metcalf, C. A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R. M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S. P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J. T.; Broudy, M. I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N. I.; Mohemmad, Q. K.; Iuliucci, J.; Rivera, V. M.; Dalgarno, D. C.; Sawyer, T. K.; Clackson, T.; Shakespeare, W. C. Discovery of 3-[2-(imidazo[1, 2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin- 1-yl) methyl]-3-(trifluoromethyl) phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster regionabelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J. Med. Chem., 2010, 53, 4701-4719.
74. Zhou, T.; Commodore, L.; Huang, W. S.; Wang, Y.; Thomas, M.; Keats, J.; Xu, Q.; Rivera, V. M.; Shakespeare, W. C.; Clackson, T.; Dalgarno, D. C.; Zhu, X. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem. Biol. Drug Des., 2011, 77, 1-11.
75. Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C. A., 3rd; Bohacek, R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.; Bornmann, W. G.; Clarkson, B.; Dalgarno, D. C.; Sawyer, T. K.; Daley, G. Q. Activity of dual SRC-ABL inhibitors highlights the role of BCR-ABL kinase dynamics in drug resistance. Proc. Natl. Acad. Sci. U S A, 2006, 103, 9244-9249. (Pubitemid 43902563)
76. nd Annual Meeting, Orlando (FL), USA, December 4-7, 2010, Abstract # 210.
77. Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE). http://clinicaltrials.gov/ct2/show?term= ponatinib&rank=1.
78. Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies, http://clinicaltrials.gov/ct2/show?term= ponatinib&rank=2.
79. Zou, D.; Huang, W.-S.; Thomas, R. M.; Romero, J. A. C.; Qi, J.; Wang, Y.; Zhu, X.; Shakespeare, W. C.; Sundaramoorthi, R.; Metcalf, C. A. III; Dalgarno, D. C.; Sawyer, T. K. Bicyclic heteroaryl compounds. W. O. Patent 2007/075869 A2, July 5, 2007.
80. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. Bosutinib: a review of preclinical studies in chronic myelogenous leukemia. Eur. J. Cancer, 2010, 46, 1781-1789.
81. Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 2009, 23, 477-485.
82. (a) Wang, Y. D.; Miller, K.; Boschelli, D. H.; Ye, F.; Wu, B.; Floyd, M. B.; Powell, D. W.; Wissner, A.; Weber, J. M.; Boschelli, F. Inhibitors of Src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett., 2000, 10, 2477-2480.
83. (b) Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem., 2001, 44, 3965-3977. (Pubitemid 33051486)
84. Sutherland, K. W.; Feigelson, G. B.; Boschelli, D. H.; Blum, D. M.; Strong, H. L. Process for preparation of 4-amino-3-quinolinecarbonitriles. U. S. Patent 2005/0043537 A1, February 24, 2005.
85. Yin, X. J.; Xu, G. H.; Sun, X.; Peng, Y.; Ji, X.; Jiang K.; Li, F. Synthesis of bosutinib from 3-methoxy-4-hydroxybenzoic acid. Molecules, 2010, 15, 4261-4266.
86. Santos, F. P.; Kantarjian, H.; Cortes, J.; Quintas-Cardama, A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr. Opin. Investig. Drugs, 2010, 11, 1450-1465.
87. Horio, T.; Hamasaki, T.; Inoue, T.; Wakayama, T.; Itou, S.; Naito, H.; Asaki, T.; Hayase, H.; Niwa, T. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg. Med. Chem. Lett., 2007, 17, 2712-2717. (Pubitemid 46636265)
88. Asaki, T.; Sugiyama, Y.; Hamamoto, T.; Higashioka, M.; Umehara, M.; Naito, H.; Niwa, T. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 1421-1425. (Pubitemid 43143035)
89. McFarland, K. L.; Wetzstein, G. A. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control, 2009, 16, 132-140.
90. Zhang, B.; Strauss; A. C.; Chu, S.; Li, M.; Ho, Y.; Shiang, K. D.; Snyder, D. S.; Huettner, C. S.; Shultz, L.; Holyoake, T.; Bhatia, R. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell, 2010, 17, 427-442.
91. Fiskus, W.; Pranpat, M.; Bali, P.; Balasis, M.; Kumaraswamy, S.; Boyapalle, S.; Rocha, K.; Wu, J.; Giles, F.; Manley, P. W.; Atadja, P.; Bhalla, K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood, 2006, 108, 645-652. (Pubitemid 44061366)
92. Gontarewicz, A.; Brümmendorf, T. H. Danusertib (formerly PHA-739358)-a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Res. Cancer Res., 2010, 184, 199-214.
93. Cortes, J.; Quintás-Cardama, A.; Garcia-Manero, G.; O'Brien, S.; Jones, D.; Faderl, S.; Ebarb, T.; Giles, F.; Thomas, D.; Kantarjian, H. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, 110, 2000-2006. (Pubitemid 350036859)
94. Borthakur, G.; Kantarjian, H.; Daley, G.; Talpaz, M.; O'Brien, S.; Garcia-Manero, G.; Giles, F.; Faderl, S.; Sugrue, M.; Cortes, J. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006, 106, 346-352. (Pubitemid 43100443)
95. Zhang, J.; Adrián, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G. R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature, 2010, 463, 501-506.
96. Fava, C.; Saglio, G. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? Semin. Hematol., 2010, 47, 319-326.
97. Takahashi, S. Combination therapy with arsenic trioxide for haematological malignancies. Anticancer Agents Med. Chem., 2010, 10, 504-510.
98. Fang, B.; Li, N.; Song, Y.; Han, Q.; Zhao, R. C. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann. Hematol., 2010, 89, 1099-1105.
99. Quintás-Cardama, A.; Kantarjian, H.; Cortes, J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer, 2009, 115, 5382-5393.
100. Quintás-Cardama, A.; Kantarjian, H.; Cortes, J. Third-generation tyrosine kinase inhibitors and beyond. Semin. Hematol., 2010, 4, 371-380.
101. Choi, H. G.; Ren, P.; Adrian, F.; Sun, F.; Lee, H. S.; Wang, X.; Ding, Q.; Zhang, G.; Xie, Y.; Zhang, J.; Liu, Y.; Tuntland, T.; Warmuth, M.; Manley, P. W. Mestan, J.; Gray, N. S.; Sim, T. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J. Med. Chem., 2010, 53, 5439-5448.
102. Weisberg, E.; Choi, H. G.; Ray, A.; Barrett, R.; Zhang, J.; Sim, T.; Zhou, W.; Seeliger, M.; Cameron, M.; Azam, M.; Fletcher, J. A.; Debiec-Rychter, M.; Mayeda, M.; Moreno, D.; Kung, A. L.; Janne, P. A.; Khosravi-Far, R.; Melo, J. V.; Manley, P. W.; Adamia, S.; Wu, C.; Gray, N.; Griffin, J. D. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 2010, 115, 4206-4216.
103. Santos, F. P.; Quintás-Cardama, A. New Drugs for Chronic Myelogenous Leukemia. Curr. Hematol. Malig. Rep., 2011, DOI: 10.1007/s11899-011-0079-9.
104. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J. Flying under the radar: the new wave of BCR-ABL inhibitor. Nat. Rev. Drug. Disc., 2007, 6, 834-848. (Pubitemid 47500507)
105. Petrelli, A.; Giordano, S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem., 2008, 15, 422-32. (Pubitemid 351472408)
106. Radich, J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin. Hematol., 2010, 47, 354-361.
107. Klyuchnikov, E.; Kröger, N.; Brummendorf, T. H.; Wiedemann, B.; Zander, A. R.; Bacher, U. Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myelogenous leukemia (CML). Biol. Blood Marrow Transplant, 2010, 16, 301-310.
108. Christoffersen, T.; Guren, T. K.; Spindler, K. L.; Dahl, O.; Lønning, P. E.; Gjertsen, B. T. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur. J. Pharmacol., 2009, 625, 6-22.
109. Aggarwal, S. Targeted cancer therapy. Nat. Rev. Drug Disc., 2010, 9, 427-428.
110. Hantschel, O.; Rix, U.; Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia & Lymphoma, 2008, 49, 615-619. (Pubitemid 351517198)
111. Rix, U.; Hantschel, O.; Durnberger, G.; Remsing Rix, L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Koecher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063. (Pubitemid 350248462)